You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CE

Adjuvant Therapies in HR+/HER2- Early Breast Cancer: A 3-Step Plan to Improve Adherence and Persistence

  • Authors: Sarah Donahue, MPH, NP, AOCNP; Karen Drucker, NP, RN; Alessandra Milani, PhD; Victoria M.L. Harmer, PhD, MBA, AKC
  • CE Released: 9/22/2022
  • Valid for credit through: 9/22/2023
Start Activity

  • Credits Available

    Nurses - 0.50 ANCC Contact Hour(s) (0.5 contact hours are in the area of pharmacology)

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This activity is intended for non-UK nurses, nurse practitioners, and physician assistants.

The goal of this activity is that learners will be better able to educate nurses on best practices for monitoring and communication in order to improve adherence and persistence in patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative early breast cancer (EBC) who are being treated with adjuvant therapy.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Adverse event (AE) profiles of oral adjuvant therapies used for HR-positive, HER2-negative EBC
  • Have greater competence related to
    • Applying various clinical tools that could improve adherence to oral adjuvant therapy in patients with HR-positive, HER2-negative EBC
    • Managing AEs of oral adjuvant therapies used for HR-positive, HER2-negative EBC
  • Demonstrate greater confidence in their ability to
    • Communicate a treatment plan to patients who are initiating adjuvant therapy for HR-positive, HER2-negative EBC


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.


Moderator

  • Sarah Donahue, MPH, NP, AOCNP

    Nurse Practitioner 
    Helen Diller Comprehensive Cancer Center 
    University of California, San Francisco
    San Francisco, California, United States

    Disclosures

    Sarah Donahue, MPH, NP, AOCNP, has the following relevant financial relationships: 
    Consultant or advisor for: Sanofi Genzyme 

Faculty

  • Karen Drucker, NP, RN

    Adult Care Nurse Practitioner
    Memorial Sloan-Kettering Cancer Center
    New York, New York, United States

    Disclosures

    Karen Drucker, NP, RN has no relevant financial relationships.

  • Alessandra Milani, PhD

    Director, Nursing School
    European Institute of Oncology
    Professor of Nursing
    University of Milan
    Milan, Italy

    Disclosures

    Alessandra Milani, MD, has no relevant financial relationships.

  • Victoria M.L. Harmer, PhD, MBA, AKC

    Consultant Nurse
    Imperial College Healthcare NHS Trust
    London, United Kingdom

    Disclosures

    Victoria M.L. Harmer PhD, MBA, AKC has the following relevant financial relationships: 
    Consultant or advisor for: Gilead; Lilly; Napp Pharmaceuticals; Novartis; Pfizer; Roche
    Speaker or member of speakers bureau for: Lilly; Napp Pharmaceuticals; Novartis; Pfizer; Roche

Editors

  • Victoria Phoenix, BS

    Medical Education Director

    Disclosures

    Victoria Phoenix, MS, has no relevant financial relationships.

  • Yoji Yamaguchi, MA, ELS

    Scientific Content Manager

    Disclosures

    Yoji Yamaguchi, MA, ELS, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Lisa Simani, APRN, MS, ACNP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Lisa Simani, APRN, MS, ACNP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Nurses

  • Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CE

Adjuvant Therapies in HR+/HER2- Early Breast Cancer: A 3-Step Plan to Improve Adherence and Persistence

Authors: Sarah Donahue, MPH, NP, AOCNP; Karen Drucker, NP, RN; Alessandra Milani, PhD; Victoria M.L. Harmer, PhD, MBA, AKCFaculty and Disclosures

CE Released: 9/22/2022

Valid for credit through: 9/22/2023

processing....

Transcrição em português

Download the pdf.

« Return to: Adjuvant Therapies in HR+/HER2- Early Breast Cancer: A 3-Step Plan to Improve Adherence and Persistence